Sermorelin and Progesterone HRT: What You Need to Know Before Combining Them

What Happens When You Take Sermorelin and Progesterone Together

The interaction between sermorelin and progesterone is a pharmacodynamic one, not a pharmacokinetic one. Neither drug meaningfully inhibits or induces the other's metabolism.

Sermorelin is a synthetic 29-amino-acid analogue of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotroph cells and stimulates pulsatile growth hormone (GH) release. Sermorelin's FDA labeling describes mild sedation and drowsiness as known adverse effects, thought to relate partly to GH's own downstream actions on sleep architecture.

Oral micronized progesterone (Prometrium, or compounded equivalent) is a potent positive allosteric modulator of the GABA-A receptor through its neuroactive steroid metabolite allopregnanolone. A 2018 review in the Journal of Neuroendocrinology confirmed that allopregnanolone acts at the same benzodiazepine-adjacent binding site that produces sedation, anxiolysis, and hypnosis. That is why clinicians prescribe oral progesterone at bedtime for perimenopausal sleep disruption: the sedation is a therapeutic feature, not just a side effect.

When you add sermorelin's sedative signal on top of progesterone's GABAergic activity, the CNS depression is additive. You may feel more groggy the next morning, experience blunted alertness, or notice vivid dreams. Falls risk, particularly in women over 60, is the most serious practical concern.

Pharmacokinetic Profile: Why CYP Enzymes Matter Less Here

Sermorelin is a peptide drug. It does not pass through CYP3A4, CYP2D6, or any major hepatic enzyme pathway in a clinically meaningful way; peptide hormones are degraded by plasma and tissue proteases. Progesterone is metabolized primarily by CYP3A4 and CYP2C19, but because sermorelin does not touch those enzymes, there is no pharmacokinetic drug-drug interaction to worry about.

This matters because it means you cannot "separate" the interaction by spacing doses across the day, the way you might with two CYP-competing drugs. The additive sedation from allopregnanolone accumulates regardless of whether sermorelin is given in the morning or at night, though the peak sedative overlap is worst when both drugs are taken within a few hours of each other.

P-glycoprotein and Blood-Brain Barrier Transport

P-glycoprotein (P-gp) is not a relevant efflux transporter for either sermorelin or progesterone at standard clinical doses. No dose adjustment based on P-gp status is required.

How the Menstrual Cycle and Hormonal Status Change This Interaction

This is where women's physiology makes a real difference, and most generic drug-interaction databases ignore it entirely.

Reproductive-Age Women

If you are still cycling, your endogenous progesterone surges in the luteal phase (roughly days 15-28 of a 28-day cycle). Serum progesterone can reach 10-30 ng/mL in the mid-luteal phase, which means your brain's GABA-A receptors are already exposed to higher allopregnanolone levels during the second half of your cycle. Adding exogenous oral progesterone on top of that creates a larger GABAergic burden than adding the same dose in the follicular phase, when endogenous progesterone is near zero.

GH secretion also varies with your cycle. A study in the Journal of Clinical Endocrinology and Metabolism found that GH pulse amplitude is higher during the follicular phase, partly because estrogen sensitizes pituitary somatotrophs to GHRH. If you use sermorelin for GH optimization and you are still cycling, your clinician should be aware that your GH response to sermorelin may be lower in the luteal phase, and sedation risk may be higher at the same time.

Perimenopause

Perimenopause is the life stage where this combination is most commonly prescribed, and it carries the most nuance.

Estrogen levels fluctuate erratically in perimenopause, which disrupts the estrogen-mediated sensitization of somatotroph cells. GH secretion declines. Population data from the Study of Women's Health Across the Nation (SWAN) showed that GH-axis blunting accelerates in the menopausal transition. Clinicians prescribing sermorelin in this window often do so for sleep, body composition, and energy, goals that overlap with the reasons progesterone is started for perimenopausal sleep disruption.

The concern: both drugs are being used partly for sleep. Their sedative effects are compounding toward the same therapeutic target. This is not automatically dangerous, but it does mean the sedation risk is harder to separate from the therapeutic benefit.

Postmenopause

After menopause, endogenous progesterone is negligible. Exogenous oral micronized progesterone at 100-200 mg nightly is standard practice when combined with estrogen therapy, as recommended by The Menopause Society's 2023 position statement. GH levels are further reduced, and the somatotroph response to sermorelin may be blunted, particularly without adequate estrogen on board.

A study in Menopause found that GH secretion in response to GHRH stimulation was lower in postmenopausal women not on estrogen compared to those receiving transdermal estradiol. This suggests that if you are combining sermorelin with progesterone-only HRT without estrogen, your GH response may be suboptimal. Adding estradiol to the regimen is likely to improve sermorelin's efficacy, though your prescriber must weigh all the hormonal therapy risks and benefits specific to your history.

Sedation: The Clinical Picture You Should Expect

Sedation from this combination is not always dramatic. For many women, the effect is a deeper, more consolidated sleep, which they interpret as a benefit. For others, it presents as:

• Morning grogginess lasting more than 90 minutes after waking
• Difficulty concentrating before noon
• Vivid or unusual dreams
• Increased daytime drowsiness if progesterone dose is high or taken too early in the evening

The FDA label for Prometrium lists somnolence in 45% of patients in the clinical trial data at the 300 mg dose, compared to 31% on placebo. At the standard 200 mg bedtime dose used in HRT, somnolence rates were lower but still clinically meaningful.

Sermorelin's own labeling describes somnolence as an adverse effect in a minority of patients, though the frequency was not quantified as precisely because clinical trial sizes were smaller.

The additive risk is a clinical inference from the known mechanisms of both drugs, not a figure derived from a head-to-head trial in women. This is an evidence gap you should know about.

A Practical Timing Framework for Minimizing Sedation Overlap

Given the pharmacodynamic overlap, here is a structured approach that can guide the conversation with your prescriber:

1. Take oral progesterone at bedtime (10-11 PM). This is already standard practice. Peak allopregnanolone levels occur roughly 2-3 hours after an oral dose.
2. Take sermorelin at bedtime as well, 30-60 minutes before sleep. GH release is most physiologically timed to early slow-wave sleep. The overlap in sedation timing, while additive, may be therapeutically exploited: both drugs deepen sleep quality.
3. If morning grogginess persists beyond 8 weeks, discuss with your prescriber whether reducing progesterone to 100 mg (if endometrial protection allows), switching to vaginal progesterone (which avoids the hepatic first-pass conversion to allopregnanolone), or adjusting sermorelin dose is appropriate.
4. Avoid alcohol on nights when both drugs are taken. Alcohol is also a GABA-A modulator and will triple-stack the sedation.
5. Do not drive within 8 hours of taking either drug until you know how the combination affects you personally.

Who Is a Good Candidate for This Combination (and Who Is Not)

Life Stages and Conditions Where This Combination Is Often Appropriate

• Perimenopausal women with sleep disruption, declining GH, and vasomotor symptoms who need both endometrial protection from progesterone and GH-axis support from sermorelin
• Postmenopausal women on combined estrogen-progesterone HRT who want additional support for body composition, skin, or energy and whose provider has documented low IGF-1 levels
• Women with PCOS who have documented GH-axis blunting and who are prescribed progesterone for cycle regulation or endometrial protection. GH secretion is often dysregulated in PCOS, and sermorelin has been studied as a way to normalize GH pulsatility, though PCOS-specific randomized data for sermorelin in women is thin.

Situations That Warrant Extra Caution or Alternative Approaches

• Women over 65 with any history of falls, balance problems, or sleep apnea. Additive sedation in this group carries real harm potential.
• Women on additional CNS depressants (benzodiazepines, gabapentin, antihistamines, opioids). The sedation stack grows with each agent. The FDA's 2020 guidance on CNS depressant combinations underscores that additive CNS depression can be unpredictably severe.
• Women with untreated obstructive sleep apnea. GH itself (stimulated by sermorelin) can worsen upper airway tone in some patients. Progesterone has mixed effects on respiratory drive. If sleep apnea is suspected, screening before starting either drug is advisable.
• Women with active or hormone-sensitive malignancy. Sermorelin stimulates GH and downstream IGF-1, which has mitogenic potential. No causative link to cancer has been established in the sermorelin-specific literature, but caution is warranted.

Pregnancy, Lactation, and Contraception

This section is required reading if you are of reproductive age or trying to conceive.

Sermorelin in Pregnancy

Sermorelin is not approved for use in pregnancy. There are no adequate human pregnancy safety data. Animal reproduction studies are limited. The FDA label does not assign a pregnancy category under the older A/B/C/D/X system because sermorelin was approved before the PQRS system changed labeling requirements, but the label explicitly advises discontinuation before attempting pregnancy.

GH and IGF-1 signaling is essential to normal fetal growth, and exogenous perturbation of the GH axis during organogenesis carries theoretical risks that have not been studied in controlled human trials. The conservative clinical position is to stop sermorelin before attempting conception and to use reliable contraception while on it if pregnancy is not desired.

Progesterone in Pregnancy

Oral micronized progesterone has a more nuanced pregnancy profile. Exogenous progesterone support is used in early pregnancy in women with luteal phase deficiency or recurrent pregnancy loss, and ACOG Practice Bulletin 253 and other ACOG guidance acknowledge progesterone supplementation in specific contexts. However, the formulation, dose, and route matter significantly. Oral micronized progesterone at HRT doses (100-200 mg) is not the same as the vaginal progesterone gel or 17-hydroxyprogesterone caproate used in preterm birth prevention.

If you become pregnant while on HRT-dose oral progesterone, contact your prescriber immediately rather than stopping abruptly without guidance.

Lactation

Sermorelin lactation data are absent. Peptide drugs are generally poorly absorbed from breast milk by the infant because gastric proteases degrade them, but formal pharmacokinetic data in lactating women do not exist. LactMed does not currently have an entry for sermorelin.

Oral micronized progesterone does pass into breast milk in small amounts. LactMed's progesterone entry notes that transfer is low and that no adverse effects have been documented in nursing infants, but it recommends using the lowest effective dose and monitoring the infant if progesterone is used during lactation.

The pragmatic clinical position: sermorelin should not be used during lactation given absent safety data. Progesterone at HRT doses during lactation requires an individualized risk-benefit discussion with your prescriber.

Contraception Requirement

If you are of reproductive age, using sermorelin, and not trying to conceive, use a reliable non-hormonal or hormonal contraceptive method. Sermorelin's effect on the GH axis during early pregnancy is unstudied, and the conservative position is to prevent pregnancy while on the drug.

Monitoring: What Your Clinician Should Track

If you and your provider decide to combine sermorelin and progesterone HRT, the following monitoring approach is appropriate:

Lab Monitoring

| Parameter | Timing | Why It Matters | |---|---|---| | IGF-1 (serum) | Baseline, then 8-12 weeks after starting sermorelin | Primary efficacy marker for GH-axis response | | Fasting glucose | Baseline, 3 months | GH raises insulin resistance; progesterone has mild anti-insulin effects | | Lipid panel | Baseline, annually | Progesterone's lipid effects depend on type and route | | Thyroid (TSH, free T4) | Baseline | GH therapy can unmask hypothyroidism; a known interaction documented in FDA GH labeling | | Endometrial assessment | Per HRT guidelines | Standard with any progestogen HRT |

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults recommends IGF-1 monitoring every 6-12 months once stable, titrating GH secretagogue dose to keep IGF-1 in the age- and sex-adjusted reference range, not the upper limit.

Clinical Monitoring

Ask your provider to assess sedation severity at every follow-up visit, specifically using a standardized question rather than a casual "how are you sleeping?" The Epworth Sleepiness Scale, a validated 8-item questionnaire, takes under 2 minutes and provides a reproducible score. Its clinical validity is well established.

A score above 10 on the Epworth scale while on this combination should trigger a reassessment of both drugs.

Specific Drug Interactions Beyond Progesterone

Sermorelin has a handful of other documented or mechanistically plausible interactions that matter in the context of women's HRT regimens:

• Glucocorticoids (prednisone, hydrocortisone): The sermorelin FDA label explicitly warns that glucocorticoids inhibit the GH response to GHRH analogues. If you take corticosteroids for an autoimmune condition or adrenal insufficiency, sermorelin may not work as expected.
• Thyroid hormone (levothyroxine): Hypothyroidism blunts the GH axis. Untreated or undertreated hypothyroidism reduces sermorelin's efficacy. Women have hypothyroidism at roughly 5-10 times the rate of men, making thyroid status a women's-health-specific check before starting sermorelin.
• Insulin and insulin sensitizers: GH raises blood glucose; sermorelin-driven GH increases may require reassessment of diabetes medications in women with type 2 diabetes or insulin-resistant PCOS.
• Other CNS depressants: As noted above, additive sedation risk applies to any agent that acts at GABA-A or other inhibitory receptors.

Estradiol (the other component of most combined HRT) does not appear to interact adversely with sermorelin at the pharmacokinetic level. Estrogen actually improves sermorelin's efficacy by enhancing somatotroph sensitivity, as noted earlier.

What the Evidence Gap Means for You

No randomized controlled trial has studied the sermorelin-plus-progesterone combination in women specifically. The drug-interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the interaction as moderate severity based on pharmacodynamic reasoning and the known CNS profiles of each drug, not on human trial data.

This is an honest limitation. The interaction profile described in this article is built from:

1. The mechanism of each drug (well-established)
2. The pharmacology of allopregnanolone and the GABA-A receptor (well-established)
3. The FDA labeling for both drugs
4. Women-specific GH physiology data from SWAN and other cohort studies
5. Clinical inference about additive sedation, which is biologically plausible but not yet proven in a controlled trial

The absence of a head-to-head trial does not mean the combination is unsafe. It means the evidence base is extrapolated rather than directly generated. Your prescriber should acknowledge this when discussing the plan with you.